Lancet Neurology, The, ISSN 1474-4422, 2011, Volume 10, Issue 10, pp. 898 - 908
Summary Background Background The leucine-rich repeat kinase 2 gene ( LRRK2 ) harbours highly penetrant mutations that are linked to familial parkinsonism....
Neurology | POPULATION | SIFT | METAANALYSIS | RISK-FACTOR | GENE | TRAITS | PROTEIN FUNCTION | CHALLENGES | CLINICAL NEUROLOGY | GENOME-WIDE ASSOCIATION | COMPREHENSIVE ANALYSIS | Genetic Predisposition to Disease | Gene Frequency | Humans | Middle Aged | Risk Factors | Protein-Serine-Threonine Kinases - genetics | Exons - genetics | Genotype | Male | International Cooperation | Parkinson Disease - genetics | Case-Control Studies | Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | Young Adult | Ethnic Groups - genetics | Adolescent | Aged, 80 and over | Polymorphism, Single Nucleotide - genetics | Adult | Female | Aged | Genome-Wide Association Study - methods | Medical colleges | Medical research | Neurosciences | Parkinson's disease | Lubrication and lubricants | Medicine, Experimental | Biological apparatus and supplies | Genetics | Agriculture | Disease susceptibility | Diagnostic imaging | Biometry | Neurologi | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Neurology | POPULATION | SIFT | METAANALYSIS | RISK-FACTOR | GENE | TRAITS | PROTEIN FUNCTION | CHALLENGES | CLINICAL NEUROLOGY | GENOME-WIDE ASSOCIATION | COMPREHENSIVE ANALYSIS | Genetic Predisposition to Disease | Gene Frequency | Humans | Middle Aged | Risk Factors | Protein-Serine-Threonine Kinases - genetics | Exons - genetics | Genotype | Male | International Cooperation | Parkinson Disease - genetics | Case-Control Studies | Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | Young Adult | Ethnic Groups - genetics | Adolescent | Aged, 80 and over | Polymorphism, Single Nucleotide - genetics | Adult | Female | Aged | Genome-Wide Association Study - methods | Medical colleges | Medical research | Neurosciences | Parkinson's disease | Lubrication and lubricants | Medicine, Experimental | Biological apparatus and supplies | Genetics | Agriculture | Disease susceptibility | Diagnostic imaging | Biometry | Neurologi | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10086, pp. 2317 - 2327
Summary Background Patients who have had inadequate response to tumour necrosis factor inhibitors have fewer treatment options and are generally more treatment...
Internal Medicine | INTERLEUKIN-17A | CRITERIA | CELLS | MEDICINE, GENERAL & INTERNAL | SECUKINUMAB | ADALIMUMAB | EFFICACY | SAFETY | MONOCLONAL-ANTIBODY | PROGRESSION | DISEASE-ACTIVITY | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Global Health | Arthritis, Psoriatic - drug therapy | Humans | Middle Aged | Female | Male | Treatment Outcome | Tumor Necrosis Factors - therapeutic use | Dermatologic Agents - therapeutic use | Clinical trials | Monoclonal antibodies | Care and treatment | Psoriatic arthritis | Necrosis | Interleukins | Product development | Therapy | Pathogenesis | Funding | Interleukin | Arthritis | Criteria | Immunotherapy | Tumor necrosis factor-TNF | Safety | Diagnosis | Dosing | Signs and symptoms | Biological products | Effectiveness | Psoriasis | Cytokines | Therapeutic applications | Injection | Patients | Inhibitors | Tumor necrosis factor | TNF inhibitors | Fatalities
Internal Medicine | INTERLEUKIN-17A | CRITERIA | CELLS | MEDICINE, GENERAL & INTERNAL | SECUKINUMAB | ADALIMUMAB | EFFICACY | SAFETY | MONOCLONAL-ANTIBODY | PROGRESSION | DISEASE-ACTIVITY | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Global Health | Arthritis, Psoriatic - drug therapy | Humans | Middle Aged | Female | Male | Treatment Outcome | Tumor Necrosis Factors - therapeutic use | Dermatologic Agents - therapeutic use | Clinical trials | Monoclonal antibodies | Care and treatment | Psoriatic arthritis | Necrosis | Interleukins | Product development | Therapy | Pathogenesis | Funding | Interleukin | Arthritis | Criteria | Immunotherapy | Tumor necrosis factor-TNF | Safety | Diagnosis | Dosing | Signs and symptoms | Biological products | Effectiveness | Psoriasis | Cytokines | Therapeutic applications | Injection | Patients | Inhibitors | Tumor necrosis factor | TNF inhibitors | Fatalities
Journal Article
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10168, pp. 253 - 264
Maintenance therapy following autologous stem cell transplantation (ASCT) can delay disease progression and prolong survival in patients with multiple myeloma....
DIAGNOSED MULTIPLE-MYELOMA | DEXAMETHASONE | HIGH-DOSE THERAPY | IMPROVES SURVIVAL | BORTEZOMIB | THALIDOMIDE | INDUCTION | LENALIDOMIDE MAINTENANCE | CHEMOTHERAPY | MEDICINE, GENERAL & INTERNAL | Therapy | Transplants & implants | Toxicity | Multiple myeloma | Medical services | Clinical trials | Stem cell transplantation | Transplantation | Peripheral neuropathy | Randomization | Motivation | Melphalan | Diagnosis | Safety | Drug dosages | Autografts | Cell survival | Hematology | Maintenance | Patients | Survival | Chemotherapy | Stem cells | Adults | Tourmaline | Pharmaceuticals | Index Medicus | Abridged Index Medicus
DIAGNOSED MULTIPLE-MYELOMA | DEXAMETHASONE | HIGH-DOSE THERAPY | IMPROVES SURVIVAL | BORTEZOMIB | THALIDOMIDE | INDUCTION | LENALIDOMIDE MAINTENANCE | CHEMOTHERAPY | MEDICINE, GENERAL & INTERNAL | Therapy | Transplants & implants | Toxicity | Multiple myeloma | Medical services | Clinical trials | Stem cell transplantation | Transplantation | Peripheral neuropathy | Randomization | Motivation | Melphalan | Diagnosis | Safety | Drug dosages | Autografts | Cell survival | Hematology | Maintenance | Patients | Survival | Chemotherapy | Stem cells | Adults | Tourmaline | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10167, pp. 143 - 155
Effective two-drug regimens could decrease long-term drug exposure and toxicity with HIV-1 antiretroviral therapy (ART). We therefore aimed to evaluate the...
ABACAVIR | MEDICINE, GENERAL & INTERNAL | THERAPY | ONCE-DAILY DOLUTEGRAVIR | SAFETY | OPEN-LABEL | INHIBITORS | TENOFOVIR/EMTRICITABINE | RITONAVIR | Anti-Retroviral Agents - therapeutic use | Emtricitabine - adverse effects | Emtricitabine - therapeutic use | Tenofovir - adverse effects | Double-Blind Method | Tenofovir - therapeutic use | Anti-HIV Agents - adverse effects | HIV Infections - virology | Humans | Middle Aged | Anti-Retroviral Agents - adverse effects | Male | RNA, Viral - blood | Lamivudine - adverse effects | HIV-1 - isolation & purification | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Lamivudine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Drug Therapy, Combination | Viral Load - drug effects | Clinical trials | Antiviral agents | HIV (Viruses) | Analysis | Anti-HIV agents | Health care | Emtricitabine | Antiretroviral drugs | Therapy | Tablets | Toxicity | Lamivudine | Infections | Exposure | Ribonucleic acid--RNA | Drug resistance | Antiretroviral therapy | Tenofovir | Randomization | Motivation | Antiretroviral agents | Human immunodeficiency virus--HIV | Adults | Safety | Drug therapy
ABACAVIR | MEDICINE, GENERAL & INTERNAL | THERAPY | ONCE-DAILY DOLUTEGRAVIR | SAFETY | OPEN-LABEL | INHIBITORS | TENOFOVIR/EMTRICITABINE | RITONAVIR | Anti-Retroviral Agents - therapeutic use | Emtricitabine - adverse effects | Emtricitabine - therapeutic use | Tenofovir - adverse effects | Double-Blind Method | Tenofovir - therapeutic use | Anti-HIV Agents - adverse effects | HIV Infections - virology | Humans | Middle Aged | Anti-Retroviral Agents - adverse effects | Male | RNA, Viral - blood | Lamivudine - adverse effects | HIV-1 - isolation & purification | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Lamivudine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Drug Therapy, Combination | Viral Load - drug effects | Clinical trials | Antiviral agents | HIV (Viruses) | Analysis | Anti-HIV agents | Health care | Emtricitabine | Antiretroviral drugs | Therapy | Tablets | Toxicity | Lamivudine | Infections | Exposure | Ribonucleic acid--RNA | Drug resistance | Antiretroviral therapy | Tenofovir | Randomization | Motivation | Antiretroviral agents | Human immunodeficiency virus--HIV | Adults | Safety | Drug therapy
Journal Article
04/2018
JINST 13 (2018) P06015 The CMS muon detector system, muon reconstruction software, and high-level trigger underwent significant changes in 2013-2014 in...
Journal Article
Journal of High Energy Physics (Online), ISSN 1029-8479, 05/2018, Volume 2018, Issue 11
JHEP 11 (2018) 042 A search in energetic, high-multiplicity final states for evidence of physics beyond the standard model, such as black holes, string balls,...
Physics - High Energy Physics - Experiment | Beyond Standard Model | Hadron-Hadron scattering (experiments) | PHYSICS OF ELEMENTARY PARTICLES AND FIELDS
Physics - High Energy Physics - Experiment | Beyond Standard Model | Hadron-Hadron scattering (experiments) | PHYSICS OF ELEMENTARY PARTICLES AND FIELDS
Journal Article
1998, Schriftenreihe zur mitteldeutschen Musikgeschichte. Serie II, Forschungsbeiträge, ISBN 3932090314, Volume Bd. 1, xl, 370
Book
Annals of Neurology, ISSN 0364-5134, 05/2011, Volume 69, Issue 5, pp. 778 - 792
Objective: We studied the independent and joint effects of the genes encoding alpha‐synuclein (SNCA) and microtubule‐associated protein tau (MAPT) in Parkinson...
COMMON VARIANTS | RISK-FACTORS | METAANALYSIS | POLYMORPHISMS | TAU-GENE | SUSCEPTIBILITY | ALPHA-SYNUCLEIN | HAPLOTYPE | NEUROSCIENCES | CLINICAL NEUROLOGY | PROGRESSIVE SUPRANUCLEAR PALSY | GENOME-WIDE ASSOCIATION | Genetic Predisposition to Disease | Humans | Middle Aged | Logistic Models | Male | Parkinson Disease - genetics | Case-Control Studies | tau Proteins - genetics | Age of Onset | Aged, 80 and over | Polymorphism, Single Nucleotide - genetics | Adult | Female | Aged | Retrospective Studies | alpha-Synuclein - genetics | Odds Ratio | Haplotypes | Genes | Parkinsons disease | Clinical Medicine | Neurologi | Neurology | Medical and Health Sciences | Medicin och hälsovetenskap | Psykiatri | Klinisk medicin | Psychiatry | Geriatrik | Geriatrics
COMMON VARIANTS | RISK-FACTORS | METAANALYSIS | POLYMORPHISMS | TAU-GENE | SUSCEPTIBILITY | ALPHA-SYNUCLEIN | HAPLOTYPE | NEUROSCIENCES | CLINICAL NEUROLOGY | PROGRESSIVE SUPRANUCLEAR PALSY | GENOME-WIDE ASSOCIATION | Genetic Predisposition to Disease | Humans | Middle Aged | Logistic Models | Male | Parkinson Disease - genetics | Case-Control Studies | tau Proteins - genetics | Age of Onset | Aged, 80 and over | Polymorphism, Single Nucleotide - genetics | Adult | Female | Aged | Retrospective Studies | alpha-Synuclein - genetics | Odds Ratio | Haplotypes | Genes | Parkinsons disease | Clinical Medicine | Neurologi | Neurology | Medical and Health Sciences | Medicin och hälsovetenskap | Psykiatri | Klinisk medicin | Psychiatry | Geriatrik | Geriatrics
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 12/2010, Volume 53, Issue 24, pp. 8627 - 8641
Urinary tract infection (UTI) by uropathogenic Escherichia coli (UPEC) is one of the most common infections, particularly affecting women. The interaction of...
MEDIATED ADHESION | TYPE-1 FIMBRIAE | CHEMISTRY, MEDICINAL | INHIBITION | AFFINITY | MANNOSE | DRUGS | FIMBRIATED ESCHERICHIA-COLI | RECEPTOR | COLONIZATION | BINDING | Humans | Cell Membrane Permeability | Host-Pathogen Interactions - drug effects | Mannosides - pharmacokinetics | Colony Count, Microbial | Blood Proteins - metabolism | Intestinal Absorption | Drug Design | Female | Urinary Tract Infections - microbiology | Urinary Bladder - microbiology | Binding, Competitive | Caco-2 Cells | Escherichia coli Infections - drug therapy | Adhesins, Escherichia coli | Administration, Oral | Solubility | Escherichia coli Infections - microbiology | Benzoates - chemical synthesis | Urinary Tract Infections - drug therapy | Anti-Bacterial Agents - chemical synthesis | Fimbriae Proteins - antagonists & inhibitors | Animals | Prodrugs - pharmacokinetics | Uropathogenic Escherichia coli - drug effects | Anti-Bacterial Agents - pharmacokinetics | Mannosides - pharmacology | Benzoates - pharmacology | Prodrugs - chemical synthesis | Protein Binding | Mannosides - chemical synthesis | Urinary Bladder - drug effects | Anti-Bacterial Agents - pharmacology | Mice | Uropathogenic Escherichia coli - enzymology | Prodrugs - pharmacology | Benzoates - pharmacokinetics
MEDIATED ADHESION | TYPE-1 FIMBRIAE | CHEMISTRY, MEDICINAL | INHIBITION | AFFINITY | MANNOSE | DRUGS | FIMBRIATED ESCHERICHIA-COLI | RECEPTOR | COLONIZATION | BINDING | Humans | Cell Membrane Permeability | Host-Pathogen Interactions - drug effects | Mannosides - pharmacokinetics | Colony Count, Microbial | Blood Proteins - metabolism | Intestinal Absorption | Drug Design | Female | Urinary Tract Infections - microbiology | Urinary Bladder - microbiology | Binding, Competitive | Caco-2 Cells | Escherichia coli Infections - drug therapy | Adhesins, Escherichia coli | Administration, Oral | Solubility | Escherichia coli Infections - microbiology | Benzoates - chemical synthesis | Urinary Tract Infections - drug therapy | Anti-Bacterial Agents - chemical synthesis | Fimbriae Proteins - antagonists & inhibitors | Animals | Prodrugs - pharmacokinetics | Uropathogenic Escherichia coli - drug effects | Anti-Bacterial Agents - pharmacokinetics | Mannosides - pharmacology | Benzoates - pharmacology | Prodrugs - chemical synthesis | Protein Binding | Mannosides - chemical synthesis | Urinary Bladder - drug effects | Anti-Bacterial Agents - pharmacology | Mice | Uropathogenic Escherichia coli - enzymology | Prodrugs - pharmacology | Benzoates - pharmacokinetics
Journal Article
1985, 1. Aufl. --, Duisburger Studien., ISBN 9783883456126, Volume Bd. 10, viii, 459
Book
Journal of Pediatrics, The, ISSN 0022-3476, 2015, Volume 167, Issue 3, pp. 627 - 632.e4
Objective To examine the current extent of the obesity problem in 2 large pediatric clinical registries in the US and Europe and to examine the hypotheses that...
Pediatrics | YOUNG-ADULTS | T1D EXCHANGE | QUALITY MANAGEMENT | INSULIN-RESISTANCE | ADOLESCENTS | DISEASE RISK-FACTORS | BODY-MASS INDEX | PEDIATRICS | WEIGHT-GAIN | METABOLIC-CONTROL | CHILDREN | Body Mass Index | Diabetes Mellitus, Type 1 - epidemiology | Glycated Hemoglobin A - analysis | United States - epidemiology | Hypoglycemia - epidemiology | Humans | Austria - epidemiology | Child, Preschool | Male | Germany - epidemiology | Obesity - epidemiology | Adolescent | Female | Registries | Child | Type 1 diabetes | Hemoglobin | Youth | Teenagers | Children | Health aspects | Obesity in adolescence | World health | Glycosylated hemoglobin
Pediatrics | YOUNG-ADULTS | T1D EXCHANGE | QUALITY MANAGEMENT | INSULIN-RESISTANCE | ADOLESCENTS | DISEASE RISK-FACTORS | BODY-MASS INDEX | PEDIATRICS | WEIGHT-GAIN | METABOLIC-CONTROL | CHILDREN | Body Mass Index | Diabetes Mellitus, Type 1 - epidemiology | Glycated Hemoglobin A - analysis | United States - epidemiology | Hypoglycemia - epidemiology | Humans | Austria - epidemiology | Child, Preschool | Male | Germany - epidemiology | Obesity - epidemiology | Adolescent | Female | Registries | Child | Type 1 diabetes | Hemoglobin | Youth | Teenagers | Children | Health aspects | Obesity in adolescence | World health | Glycosylated hemoglobin
Journal Article